Clinical Trial Update: REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania

View source ↗

Summary

A real-world study in Romania evaluates outcomes for Chronic Lymphocytic Leukemia patients treated with acalabrutinib. The study is sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Lymphocytic Leukemia | Status: ACTIVE_NOT_RECRUITING